LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Akciju saraksts・MannKind Corp

MannKind Corp

Slēgts

SektorsVeselības aprūpe

3.35 -2.05

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.3

Max

3.52

Galvenie mērījumi
By Trading Economics
Ienākumi	-671K -17M
Pārdošana	-22M 90M
P/E Sektora vidējais	140.5 49.888
EPS	-0.02
Peļņas marža	-18.431
Darbinieki	591
EBITDA	5.9M 3.4M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+142.56% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	223M 1.1B
Iepriekšējā atvēršanas cena	5.4
Iepriekšējā slēgšanas cena	3.35

Ziņu noskaņojums

By Acuity

47%

53%

144 / 344 Rangs Healthcare

MannKind Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. jūn. 23:22 UTC

Peļņas

Galvenie tirgus virzītāji

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

2026. g. 3. jūn. 23:09 UTC

Karstas akcijas

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

2026. g. 3. jūn. 20:51 UTC

Peļņas

Costco Reports 15% Sales Growth in May

2026. g. 3. jūn. 20:43 UTC

Peļņas

Broadcom 2Q Revenue Climbs on AI Chip Demand

2026. g. 3. jūn. 23:48 UTC

Tirgus saruna

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

2026. g. 3. jūn. 23:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 3. jūn. 23:35 UTC

Tirgus saruna

Oil Futures Fall on Possible Technical Correction -- Market Talk

2026. g. 3. jūn. 23:15 UTC

Tirgus saruna

Peļņas

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

2026. g. 3. jūn. 22:08 UTC

Karstas akcijas

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

2026. g. 3. jūn. 21:54 UTC

Tirgus saruna

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

2026. g. 3. jūn. 21:18 UTC

Peļņas

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

2026. g. 3. jūn. 21:15 UTC

Peļņas

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

2026. g. 3. jūn. 21:13 UTC

Peļņas

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

2026. g. 3. jūn. 21:13 UTC

Peļņas

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

2026. g. 3. jūn. 21:12 UTC

Peļņas

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

2026. g. 3. jūn. 21:09 UTC

Peļņas

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

2026. g. 3. jūn. 21:03 UTC

Peļņas

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

2026. g. 3. jūn. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. jūn. 20:43 UTC

Peļņas

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

2026. g. 3. jūn. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

2026. g. 3. jūn. 20:37 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

2026. g. 3. jūn. 20:35 UTC

Peļņas

Broadcom Stock Falls Despite Record Results -- Barrons.com

2026. g. 3. jūn. 20:21 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

2026. g. 3. jūn. 20:17 UTC

Peļņas

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

2026. g. 3. jūn. 20:17 UTC

Peļņas

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

2026. g. 3. jūn. 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

2026. g. 3. jūn. 20:15 UTC

Peļņas

Broadcom 2Q Adj EPS $2.44 >AVGO

2026. g. 3. jūn. 20:15 UTC

Peļņas

Broadcom 2Q EPS $1.91 >AVGO

2026. g. 3. jūn. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 3. jūn. 20:15 UTC

Peļņas

Broadcom 2Q Rev $22.19B >AVGO

Salīdzinājums

Cenas izmaiņa

MannKind Corp Prognoze

Cenas mērķis

By TipRanks

142.56% augšup

Prognoze 12 mēnešiem

Vidējais 8.15 USD 142.56%

Augstākais 11 USD

Zemākais 4.75 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi MannKind Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam MannKind Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

144 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.